Pulse Biosciences, Inc. (PLSE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulse Biosciences, Inc. on April 25, 2026. The filing discloses Regulation FD information regarding late-breaking updated data from the first-in-human clinical study of the Company's nPulse Cardiac Catheter System, a device designed to treat atrial fibrillation. The findings were presented at Heart Rhythm 2026 in Chicago, Illinois.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain financial statements or operational financial data.
Material Changes and Clinical Findings
The primary material event is the announcement of key findings from the nPulse Cardiac Catheter System study. Significant clinical metrics include:
- Procedural Success: Sustained 100% success rate at 6 months (95/95 evaluable patients) and 96% at one year (51/53 evaluable patients) by holter.
- Freedom from Arrhythmia: Sustained 90% Kaplan-Meier estimate of freedom from AF/AFL/AT at one year.
- Procedural Efficiency:
- Left atrial dwell time: 18.6 ± 13.0 minutes.
- Total procedure time: 60.2 ± 27.7 minutes.
- Fluoroscopy time: 9.4 ± 5.9 minutes.
- Average applications per-patient for PVI: 12.3 ± 2.6.
- Safety Profile: Low serious adverse event (SAE) rate, with 1.7% (3/177) of subjects experiencing an SAE related to the primary safety endpoint.
Guidance, Outlook, and Risks
The Company posted an updated investor presentation ("Investor Deck") on April 25, 2026, which incorporates these findings. The filing explicitly states that the Investor Deck contains forward-looking statements subject to risks and uncertainties. The Company undertakes no obligation to publicly update or revise the information in the Investor Deck or this Item 7.01, except as required by law. The information is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) and the updated Investor Deck (Exhibit 99.2) for detailed methodology and patient demographics.
- Confirm the definition of "evaluable patients" used in the success rate calculations.
- Review the Company's most recent 10-K or 10-Q filings for current financial status, as this 8-K contains no financial data.
- Assess the timeline for potential regulatory submissions or commercialization based on the one-year data presented.